Ruijun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ruijun Liu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Jianghao Ren
4 shared publicationsQiang Tan
Shanghai Lung Tumor Clinical Medicine Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China
3 shared publicationsJiazheng Huang
Shanghai Lung Tumor Clinic Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China
2 shared publicationsMingyang Zhu
Shanghai Lung Tumor Clinic Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China
2 shared publicationsQingquan Luo
Shanghai Lung Tumor Clinical Medicine Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China
2 shared publicationsTing Ren
Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Lung Tumor Clin Med Ctr, Sch Med, 241 Huaihai West Rd, Shanghai, Peoples R China
2 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 5547-5560
Aging population of tracheal, bronchus, and lung cancer: global, regional, and national burden—insights from the Global Burden of Disease Study 2021
Background: Tracheal, bronchus, and lung (TBL) cancer is the leading cause of cancer-related deaths globally and accounts for the highest incidence among all cancers. We used the Global Burden of Disease (GBD) data from 1990 to 2021 to analyze the burden of TBL cancer by age, sex, and socio-demographic index (SDI) to provide new insights. Methods: We utilized GBD 2021 methodologies to calculate the percentage change (PC) in TBL cancer age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and disability-adjusted life-years (DALYs). Age-period-cohort models predicted TBL cancer incidence and mortality trends for 2035. The elderly population (EP) was stratified as vs. ≥70 years. Results: In 2021, TBL cancer accounted for 2.28 million [95% uncertainty interval (UI): 2.06–2.51] new cases, 2.04 million (95% UI: 1.88–2.19) deaths, and 45.9 million (95% UI: 42.3–49.3) DALYs. ASIR in males declined significantly (PC =−11.2%, 95% UI: −21.7% to −0.4%), while it slightly increased in females (PC =0.9%, 95% UI: −8.3% to 11.4%). Non-elderly (vs. 15.74 per 100,000). Mortality among elderly males declined in some regions, while mortality among females, especially in low-SDI countries, showed no improvement and sometimes increased. Projections to 2035 suggest that ASIR and ASMR will continue rising in older women while declining in males. Conclusions: The burden of TBL cancer is projected to rise with population aging, particularly among women. The increasing ASIR and ASMR in females warrant urgent investigation of risk factors and targeted preventive measures to curb this trend.
- 1 August 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 5547-5560
Open AccessAging population of tracheal, bronchus, and lung cancer: global, regional, and national burden—insights from the Global Burden of Disease Study 2021
Background: Tracheal, bronchus, and lung (TBL) cancer is the leading cause of cancer-related deaths globally and accounts for the highest incidence among all cancers. We used the Global Burden of Disease (GBD) data from 1990 to 2021 to analyze the burden of TBL cancer by age, sex, and socio-demographic index (SDI) to provide new insights. Methods: We utilized GBD 2021 methodologies to calculate the percentage change (PC) in TBL cancer age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and disability-adjusted life-years (DALYs). Age-period-cohort models predicted TBL cancer incidence and mortality trends for 2035. The elderly population (EP) was stratified as vs. ≥70 years. Results: In 2021, TBL cancer accounted for 2.28 million [95% uncertainty interval (UI): 2.06–2.51] new cases, 2.04 million (95% UI: 1.88–2.19) deaths, and 45.9 million (95% UI: 42.3–49.3) DALYs. ASIR in males declined significantly (PC =−11.2%, 95% UI: −21.7% to −0.4%), while it slightly increased in females (PC =0.9%, 95% UI: −8.3% to 11.4%). Non-elderly (vs. 15.74 per 100,000). Mortality among elderly males declined in some regions, while mortality among females, especially in low-SDI countries, showed no improvement and sometimes increased. Projections to 2035 suggest that ASIR and ASMR will continue rising in older women while declining in males. Conclusions: The burden of TBL cancer is projected to rise with population aging, particularly among women. The increasing ASIR and ASMR in females warrant urgent investigation of risk factors and targeted preventive measures to curb this trend.
- Open Access
- 22 October 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (10) , 1-11
MAT1A activation of glycolysis to promote NSCLC progression depends on stabilizing CCND1
Non-small cell lung cancer (NSCLC) remains a cause for concern as the leading cause of cancer-related death worldwide. Amidst ongoing debates on the role and mechanisms of methionine adenosyltransferase 1A (MAT1A) in cancer, our study sheds light on its significance in NSCLC. Leveraging TCGA database and immunohistochemical staining, we systematically analyzed MAT1A expression in NSCLC, uncovering its marked upregulation. To unravel the functional and mechanistic underpinnings, we implemented stable knockdown of MAT1A in NSCLC cell lines. Our findings converged to demonstrate that suppression of MAT1A expression effectively impeded the proliferation and migratory capabilities of NSCLC cells, while concurrently enhancing apoptosis. Mechanistically, we discovered that MAT1A depletion accelerated the degradation of CCND1, a key cell cycle regulator, through S-phase kinase-associated protein 2 (SKP2)-mediated ubiquitination. Notably, CCND1 emerged as a crucial MAT1A partner, jointly orchestrating glycolytic metabolism in NSCLC cells. This intricate interplay suggests that MAT1A promotes NSCLC progression by safeguarding CCND1 protein stability and activating glycolytic pathways, thereby sustaining tumorigenesis. In summary, our study not only identifies MAT1A as a prognostic marker for poor survival in NSCLC patients but also elucidates its mechanistic contributions to cancer progression. These findings pave the way for the development of targeted therapies aimed at disrupting the deleterious MAT1A-CCND1-glycolysis axis in NSCLC.
- 22 October 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (10) , 1-11
Open AccessMAT1A activation of glycolysis to promote NSCLC progression depends on stabilizing CCND1
Non-small cell lung cancer (NSCLC) remains a cause for concern as the leading cause of cancer-related death worldwide. Amidst ongoing debates on the role and mechanisms of methionine adenosyltransferase 1A (MAT1A) in cancer, our study sheds light on its significance in NSCLC. Leveraging TCGA database and immunohistochemical staining, we systematically analyzed MAT1A expression in NSCLC, uncovering its marked upregulation. To unravel the functional and mechanistic underpinnings, we implemented stable knockdown of MAT1A in NSCLC cell lines. Our findings converged to demonstrate that suppression of MAT1A expression effectively impeded the proliferation and migratory capabilities of NSCLC cells, while concurrently enhancing apoptosis. Mechanistically, we discovered that MAT1A depletion accelerated the degradation of CCND1, a key cell cycle regulator, through S-phase kinase-associated protein 2 (SKP2)-mediated ubiquitination. Notably, CCND1 emerged as a crucial MAT1A partner, jointly orchestrating glycolytic metabolism in NSCLC cells. This intricate interplay suggests that MAT1A promotes NSCLC progression by safeguarding CCND1 protein stability and activating glycolytic pathways, thereby sustaining tumorigenesis. In summary, our study not only identifies MAT1A as a prognostic marker for poor survival in NSCLC patients but also elucidates its mechanistic contributions to cancer progression. These findings pave the way for the development of targeted therapies aimed at disrupting the deleterious MAT1A-CCND1-glycolysis axis in NSCLC.
- Open Access
Tracheal tunica adventitia invasion after lobectomy in patients with non-small cell lung cancer
- Open Access
- 5 May 2022
- Published by Wiley in Thoracic Cancer
- Vol. 13 (11) , 1664-1675
The outcomes of margin status after sleeve lobectomy for patients of non–small cell lung cancer
Background: Sleeve lobectomy is recognized as an alternative surgical operation to pneumonectomy because it preserves the most pulmonary function and has a considerable prognosis. In this study, we aimed to investigate the implications of residual status for patients after sleeve lobectomy.Methods: In this retrospective cohort study, we summarized 58 242 patients who underwent surgeries from 2015 to 2018 in Shanghai Chest Hospital and found 456 eligible patients meeting the criteria. The status of R2 was excluded. The outcomes were overall survival (OS) and recurrence‐free survival (RFS). We performed a subgroup analysis to further our investigation.Results: After the propensity score match, the baseline characteristic was balanced between two groups. The survival analysis showed no significant difference of overall survival and recurrence‐free survival between R0 and R1 groups (OS: p = 0.053; RFS: p = 0.14). In the multivariate Cox analysis, we found that the margin status was not a dependent risk factor to RFS (p = 0.119) and OS (p = 0.093). In the patients of R1, N stage and age were closely related to OS, but we did not find any significant risk variable in RFS for R1 status. In the subgroup analysis, R1 status may have a worse prognosis on patients with more lymph nodes examination. On further investigation, we demonstrated no differences among the four histological types of margin status.Conclusion: In our study, we confirmed that the margin status after sleeve lobectomies was not the risk factor to prognosis. However, patients with more lymph nodes resection should pay attention to the margin status.
- 5 May 2022
- Published by Wiley in Thoracic Cancer
- Vol. 13 (11) , 1664-1675
Open AccessThe outcomes of margin status after sleeve lobectomy for patients of non–small cell lung cancer
Background: Sleeve lobectomy is recognized as an alternative surgical operation to pneumonectomy because it preserves the most pulmonary function and has a considerable prognosis. In this study, we aimed to investigate the implications of residual status for patients after sleeve lobectomy.Methods: In this retrospective cohort study, we summarized 58 242 patients who underwent surgeries from 2015 to 2018 in Shanghai Chest Hospital and found 456 eligible patients meeting the criteria. The status of R2 was excluded. The outcomes were overall survival (OS) and recurrence‐free survival (RFS). We performed a subgroup analysis to further our investigation.Results: After the propensity score match, the baseline characteristic was balanced between two groups. The survival analysis showed no significant difference of overall survival and recurrence‐free survival between R0 and R1 groups (OS: p = 0.053; RFS: p = 0.14). In the multivariate Cox analysis, we found that the margin status was not a dependent risk factor to RFS (p = 0.119) and OS (p = 0.093). In the patients of R1, N stage and age were closely related to OS, but we did not find any significant risk variable in RFS for R1 status. In the subgroup analysis, R1 status may have a worse prognosis on patients with more lymph nodes examination. On further investigation, we demonstrated no differences among the four histological types of margin status.Conclusion: In our study, we confirmed that the margin status after sleeve lobectomies was not the risk factor to prognosis. However, patients with more lymph nodes resection should pay attention to the margin status.
- 22 January 2022
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 247 (8) , 641-657
Identification of a 7-miRNA signature for predicting the prognosis of patients with lung adenocarcinoma
The role of microRNAs (miRNAs) in tumor diagnosis and patients’ prognosis has recently gained extensive research attention. This study was designed to analyze miRNA in lung adenocarcinoma (LUAD) using bioinformatics analysis and to identify novel biomarkers to predict overall survival (OS) for LUAD patients. Differential miRNA expression analysis was performed on LUAD, and normal tissues were extracted from The Cancer Genome Atlas (TCGA). Univariate Cox risk regression and least absolute shrinkage and selection operator (LASSO) Cox analysis were used to screen prognostic miRNAs and develop a risk score model. The prognostic performance of the system was examined utilizing the Kaplan–Meier and receiver operating characteristic (ROC) curves. Independent prognostic factors of LUAD were determined by multivariate Cox regression analysis. Nomogram was constructed according to the independent prognostic factors to evaluate the patients’ one-, three- and five-year OS. A 7-miRNA signature based on miR-584-5p, miR-31-3p, miR-490-3, miR-4661-5p, miR-30e-5p, miR-582-5p, and miR-148a-3p was established. To categorize patients into high- and low-risk groups, the risk score was computed. The OS of the low-risk group was significantly longer than the high-risk group, and the signature showed high sensitivity and specificity in anticipating the one-, three- and five-year OS. The system was an independent factor in predicting the OS of LUAD patients and performed better when combined with the N stage in nomogram. A 7-miRNA signature developed in this study could accurately predict LUAD survival.
- 22 January 2022
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 247 (8) , 641-657
Identification of a 7-miRNA signature for predicting the prognosis of patients with lung adenocarcinoma
The role of microRNAs (miRNAs) in tumor diagnosis and patients’ prognosis has recently gained extensive research attention. This study was designed to analyze miRNA in lung adenocarcinoma (LUAD) using bioinformatics analysis and to identify novel biomarkers to predict overall survival (OS) for LUAD patients. Differential miRNA expression analysis was performed on LUAD, and normal tissues were extracted from The Cancer Genome Atlas (TCGA). Univariate Cox risk regression and least absolute shrinkage and selection operator (LASSO) Cox analysis were used to screen prognostic miRNAs and develop a risk score model. The prognostic performance of the system was examined utilizing the Kaplan–Meier and receiver operating characteristic (ROC) curves. Independent prognostic factors of LUAD were determined by multivariate Cox regression analysis. Nomogram was constructed according to the independent prognostic factors to evaluate the patients’ one-, three- and five-year OS. A 7-miRNA signature based on miR-584-5p, miR-31-3p, miR-490-3, miR-4661-5p, miR-30e-5p, miR-582-5p, and miR-148a-3p was established. To categorize patients into high- and low-risk groups, the risk score was computed. The OS of the low-risk group was significantly longer than the high-risk group, and the signature showed high sensitivity and specificity in anticipating the one-, three- and five-year OS. The system was an independent factor in predicting the OS of LUAD patients and performed better when combined with the N stage in nomogram. A 7-miRNA signature developed in this study could accurately predict LUAD survival.
- 21 September 2012
- Published by Springer Nature in Inflammation Research
- Vol. 62 (1) , 69-79
VEGF165 attenuates the Th17/Treg imbalance that exists when transplanting allogeneic skeletal myoblasts to treat acute myocardial infarction
Objectives To investigate whether Th17/Treg imbalance exists, and whether VEGF165 attenuates the imbalance in allogeneic skeletal myoblast transplantation (allo-SMT) for acute myocardial infarction (AMI). Methods On days 1, 2, 4, and 7 after allo-SMT, the percentages and ratios of Th17 and Treg cells were analyzed by flow cytometry in three groups—the AMI group, the AMI-S group (allo-SMT) and the AMI-V group (with VEGF165 treatment). Subsequently, related proinflammatory and regulatory cytokines and key transcription factors, ROR-γt mRNA and Foxp3 mRNA expression, were examined by Bio-plex and real-time polymerase chain reaction, respectively. Results On days 1, 2, 4, and 7, the percentage of Tregs, related cytokine concentrations and transcript factor Foxp3 mRNA in the AMI-S group were lower than those in the AMI group, while those in the AMI-V group were higher than those in the AMI group. However, the percentage of Th17 cells, related cytokine concentrations and ROR-γt mRNA in the AMI-S group were higher than those in the AMI group; those in the AMI-V group were lower than those in the AMI group. Compared with the AMI group, the ratios of Th17/Treg cells significantly increased in the AMI-S group and decreased in the AMI-V group. Conclusions Th17/Treg imbalance participated in the formation and development of the inflammatory and immune response after allo-SMT. However, transfected VEGF165 was able to relieve the severity of the Th17/Treg imbalance.
- 21 September 2012
- Published by Springer Nature in Inflammation Research
- Vol. 62 (1) , 69-79
VEGF165 attenuates the Th17/Treg imbalance that exists when transplanting allogeneic skeletal myoblasts to treat acute myocardial infarction
Objectives To investigate whether Th17/Treg imbalance exists, and whether VEGF165 attenuates the imbalance in allogeneic skeletal myoblast transplantation (allo-SMT) for acute myocardial infarction (AMI). Methods On days 1, 2, 4, and 7 after allo-SMT, the percentages and ratios of Th17 and Treg cells were analyzed by flow cytometry in three groups—the AMI group, the AMI-S group (allo-SMT) and the AMI-V group (with VEGF165 treatment). Subsequently, related proinflammatory and regulatory cytokines and key transcription factors, ROR-γt mRNA and Foxp3 mRNA expression, were examined by Bio-plex and real-time polymerase chain reaction, respectively. Results On days 1, 2, 4, and 7, the percentage of Tregs, related cytokine concentrations and transcript factor Foxp3 mRNA in the AMI-S group were lower than those in the AMI group, while those in the AMI-V group were higher than those in the AMI group. However, the percentage of Th17 cells, related cytokine concentrations and ROR-γt mRNA in the AMI-S group were higher than those in the AMI group; those in the AMI-V group were lower than those in the AMI group. Compared with the AMI group, the ratios of Th17/Treg cells significantly increased in the AMI-S group and decreased in the AMI-V group. Conclusions Th17/Treg imbalance participated in the formation and development of the inflammatory and immune response after allo-SMT. However, transfected VEGF165 was able to relieve the severity of the Th17/Treg imbalance.